Verona Pharma Plc (LON:VRP)‘s stock had its “corporate” rating reiterated by equities researchers at N+1 Singer in a research note issued to investors on Monday.
Verona Pharma Plc (LON:VRP) opened at 3.40 on Monday. Verona Pharma Plc has a 12-month low of GBX 2.17 and a 12-month high of GBX 5.25. The company’s market capitalization is GBX 34.34 million. The stock’s 50 day moving average price is GBX 3.19 and its 200 day moving average price is GBX 3.27.
In other Verona Pharma Plc news, insider Jan-Anders Karlsson,Sven bought 600,000 shares of the stock in a transaction on Tuesday, August 9th. The shares were purchased at an average cost of GBX 3 ($0.04) per share, with a total value of £18,000 ($23,495.63).
About Verona Pharma Plc
Verona Pharma plc is a specialist pharma company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its lead drug, RPL554, a Phosphodiesterase 3 (PDE3)/PDE4 inhibitor with both bronchodilator and anti-inflammatory activities, is in Phase II trials as a nebulized treatment for acute exacerbations of COPD in a hospital setting.
Receive News & Ratings for Verona Pharma Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma Plc and related companies with MarketBeat.com's FREE daily email newsletter.